Fibrinolytic status in acute coronary syndromes: Evidence of differences in relation to clinical features and pathophysiological pathways.

Eduard Shantsila; S Montoro-García; Luke Tapp; Stavros Apostolakis; BJ Wrigley; Gregory Lip

doi:10.1160/TH12-01-0011

Fibrinolytic status in acute coronary syndromes: Evidence of differences in relation to clinical features and pathophysiological pathways.

Eduard Shantsila
, S Montoro-García
, Luke Tapp
, Stavros Apostolakis
, BJ Wrigley
, Gregory Lip

Research output: Contribution to journal › Article

13 Citations (Scopus)

Abstract

Limited data are available on the role of innate fibrinolysis in acute coronary syndromes (ACS). In the present study we evaluated the dynamic alterations of fibrinolytic markers in patients presenting with ACS. Tissue-type-(tPA) and urokinase type-(uPA) plasminogen activators, plasminogen activator inhibitor (PAI-1) antigen and activity and thrombin activatable fibrinolysis inhibitor (TAFI) were analysed in 50 patients with ST elevation myocardial infarction (STEMI), 47 non-STEMI patients (NSTEMI), 40 patients with stable coronary artery disease (CAD) and 39 controls. The parameters were measured on day 1 and days 3, 7 and 30. Counts of monocyte subsets, monocyte-platelet aggregates and plasma inflammatory cytokines were assessed on admission. On day 1, TAFI was higher in NSTEMI vs. STEMI (p

Original language	English
Journal	Thrombosis and Haemostasis
Volume	108
Issue number	1
DOIs	https://doi.org/10.1160/TH12-01-0011
Publication status	Published - 27 Apr 2012

Access to Document

10.1160/TH12-01-0011

Cite this

@article{0b40d6c67b714bc49a7de23e38356420,

title = "Fibrinolytic status in acute coronary syndromes: Evidence of differences in relation to clinical features and pathophysiological pathways.",

abstract = "Limited data are available on the role of innate fibrinolysis in acute coronary syndromes (ACS). In the present study we evaluated the dynamic alterations of fibrinolytic markers in patients presenting with ACS. Tissue-type-(tPA) and urokinase type-(uPA) plasminogen activators, plasminogen activator inhibitor (PAI-1) antigen and activity and thrombin activatable fibrinolysis inhibitor (TAFI) were analysed in 50 patients with ST elevation myocardial infarction (STEMI), 47 non-STEMI patients (NSTEMI), 40 patients with stable coronary artery disease (CAD) and 39 controls. The parameters were measured on day 1 and days 3, 7 and 30. Counts of monocyte subsets, monocyte-platelet aggregates and plasma inflammatory cytokines were assessed on admission. On day 1, TAFI was higher in NSTEMI vs. STEMI (p",

author = "Eduard Shantsila and S Montoro-Garc{\'i}a and Luke Tapp and Stavros Apostolakis and BJ Wrigley and Gregory Lip",

year = "2012",

month = apr,

day = "27",

doi = "10.1160/TH12-01-0011",

language = "English",

volume = "108",

journal = "Thrombosis and Haemostasis",

publisher = "Schattauer",

number = "1",

}

TY - JOUR

T1 - Fibrinolytic status in acute coronary syndromes: Evidence of differences in relation to clinical features and pathophysiological pathways.

AU - Shantsila, Eduard

AU - Montoro-García, S

AU - Tapp, Luke

AU - Apostolakis, Stavros

AU - Wrigley, BJ

AU - Lip, Gregory

PY - 2012/4/27

Y1 - 2012/4/27

N2 - Limited data are available on the role of innate fibrinolysis in acute coronary syndromes (ACS). In the present study we evaluated the dynamic alterations of fibrinolytic markers in patients presenting with ACS. Tissue-type-(tPA) and urokinase type-(uPA) plasminogen activators, plasminogen activator inhibitor (PAI-1) antigen and activity and thrombin activatable fibrinolysis inhibitor (TAFI) were analysed in 50 patients with ST elevation myocardial infarction (STEMI), 47 non-STEMI patients (NSTEMI), 40 patients with stable coronary artery disease (CAD) and 39 controls. The parameters were measured on day 1 and days 3, 7 and 30. Counts of monocyte subsets, monocyte-platelet aggregates and plasma inflammatory cytokines were assessed on admission. On day 1, TAFI was higher in NSTEMI vs. STEMI (p

AB - Limited data are available on the role of innate fibrinolysis in acute coronary syndromes (ACS). In the present study we evaluated the dynamic alterations of fibrinolytic markers in patients presenting with ACS. Tissue-type-(tPA) and urokinase type-(uPA) plasminogen activators, plasminogen activator inhibitor (PAI-1) antigen and activity and thrombin activatable fibrinolysis inhibitor (TAFI) were analysed in 50 patients with ST elevation myocardial infarction (STEMI), 47 non-STEMI patients (NSTEMI), 40 patients with stable coronary artery disease (CAD) and 39 controls. The parameters were measured on day 1 and days 3, 7 and 30. Counts of monocyte subsets, monocyte-platelet aggregates and plasma inflammatory cytokines were assessed on admission. On day 1, TAFI was higher in NSTEMI vs. STEMI (p

U2 - 10.1160/TH12-01-0011

DO - 10.1160/TH12-01-0011

M3 - Article

C2 - 22538774

VL - 108

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

IS - 1

ER -

Fibrinolytic status in acute coronary syndromes: Evidence of differences in relation to clinical features and pathophysiological pathways.

Abstract

Access to Document

Fingerprint

Cite this